Khokhlova S V, Cherkasova M V, Orel N F, Limareva S V, Bazaeva I Ia, Gorbunova V A
Vestn Ross Akad Med Nauk. 2013(11):115-21.
Given the high rate of recurrence of ovarian cancer, the search for new therapeutic strategies are topical issue. According to various studies the effectiveness of drug treatment relapse depends on the platinum-free interval, increasing in proportion to its duration. If therapy is platinum-resistant recurrent ovarian cancer is a standard approach, the treatment of platinum-sensitive recurrent algorithm is not fully defined. Comparison of platinum and non-platinum combinations revealed the advantage of combined platinum- treatment for patients with platinum-free interval of more than 6 months without an increase in life expectancy. Non-platinum combination of trabected in with pegylated liposomal doxorubicin has shown comparable efficacy with an advantage in overall survival in patients with platinum-free interval of 6-12 months. A platinum-free interval prolongation by the use of non-platinum mode increases the efficiency of subsequent platinum-based therapy, increasing the life expectancy of patients. Currently under study molecular markers and prognostic factors allowing to define a group of patients who have the greatest benefit from the use trabectedin with pegylated liposomal doxorubicin as second-line chemotherapy.
鉴于卵巢癌的高复发率，寻找新的治疗策略是一个热门问题。根据各种研究，药物治疗复发的有效性取决于无铂间期，其有效性与间期时长成正比。如果治疗铂耐药复发性卵巢癌是一种标准方法，那么铂敏感复发性卵巢癌的治疗方案尚未完全明确。铂类与非铂类联合治疗的比较显示，对于无铂间期超过6个月的患者，联合铂类治疗具有优势，但并未延长预期寿命。曲贝替定与聚乙二醇化脂质体阿霉素的非铂类联合治疗已显示出相当的疗效，对于无铂间期为6至12个月的患者，其在总生存期方面具有优势。通过使用非铂类治疗模式延长无铂间期可提高后续铂类治疗的效率，延长患者的预期寿命。目前正在研究分子标志物和预后因素，以确定一组从使用曲贝替定与聚乙二醇化脂质体阿霉素作为二线化疗中获益最大的患者群体。
